✦ LIBER ✦

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

✍ Scribed by Giancarlo Comi; Nicola De Stefano; Mark S Freedman; Frederik Barkhof; Chris H Polman; Bernard MJ Uitdehaag; Florence Casset-Semanaz; Brian Hennessy; Margaretha Stam Moraga; Sanda Rocak; Bettina Stubinski; Ludwig Kappos

Book ID: 114409938
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 224 KB
Volume: 11
Category: Article
ISSN: 1474-4465
DOI: 10.1016/s1474-4422(11)70262-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interferon beta-1a for brain tissue loss

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

✍ Massimo Filippi; Marco Rovaris; Matilde Inglese; Frederik Barkhof; Nicola De Ste 📂 Article 📅 2004 🏛 The Lancet 🌐 English ⚖ 181 KB

Effect of oral cladribine on time to con

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

✍ Leist, Thomas P; Comi, Giancarlo; Cree, Bruce A C; Coyle, Patricia K; Freedman, 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 334 KB

Long-term effect of early treatment with

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

✍ Ludwig Kappos; Mark S Freedman; Chris H Polman; Gilles Edan; Hans-Peter Hartung; 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 239 KB

Efficacy of vitamin D3 as add-on therapy

Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial

✍ Joost Smolders; Raymond Hupperts; Frederik Barkhof; Luigi M.E. Grimaldi; Trygve 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 355 KB

Comparison of subcutaneous interferon be

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

✍ Daniel D Mikol; Frederik Barkhof; Peter Chang; Patricia K Coyle; Douglas R Jeffe 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 216 KB